Intrapleural Hemocoagulase Outcomes After VATS for Stage IA Lung Cancer

Yingding Ruan's retrospective study of 442 stage IA non-small cell lung cancer patients undergoing video-assisted thoracoscopic surgery (VATS), comparing outcomes between those receiving intrapleural Hemocoagulase Bothrops atrox (HBA) and a control group. The dataset, last updated on 2026-04-10, includes postoperative coagulation profiles, complication rates, and hospital length of stay, analyzed using inverse probability of treatment weighting.

Use Cases

• Analyze the association between intrapleural HBA and coagulation parameters like prothrombin time and fibrinogen levels.
• Model the relationship between HBA administration and postoperative complication rates.
• Predict postoperative hospital length of stay based on treatment group and patient characteristics.

Strengths

• Dataset includes 442 patient records, providing a substantial sample for analysis.
• Results are based on statistical adjustment (inverse probability of treatment weighting) to balance baseline characteristics.
• Specific effect sizes are reported, such as a beta of -2.06 for reduced hospital stay.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is derived from a single retrospective study, which may limit generalizability.

Provenance

Source

Yingding Ruan via figshare

Collection Method

Retrospective analysis of patient records.

Time Range

null

Freshness

Last updated 2026-04-10 05:29:35; freshness should be verified.

Geography

null